Teleflex (NYSE:TFX) PT Lowered to $219.00

Teleflex (NYSE:TFX) had its price target decreased by Truist Financial from $240.00 to $219.00 in a research report sent to investors on Friday, Benzinga reports. Truist Financial currently has a hold rating on the medical technology company’s stock.

Other equities analysts have also recently issued reports about the stock. Royal Bank of Canada dropped their price objective on shares of Teleflex from $272.00 to $265.00 and set an outperform rating on the stock in a research note on Friday, February 23rd. JMP Securities reissued a market outperform rating and set a $285.00 price target on shares of Teleflex in a report on Friday, February 23rd. StockNews.com cut Teleflex from a buy rating to a hold rating in a research report on Friday, February 23rd. Finally, Needham & Company LLC restated a hold rating on shares of Teleflex in a research note on Friday. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Teleflex currently has a consensus rating of Moderate Buy and an average price target of $261.75.

Teleflex Stock Performance

Shares of Teleflex stock opened at $200.96 on Friday. The business has a 50-day simple moving average of $216.73 and a 200-day simple moving average of $226.68. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 2.51. Teleflex has a one year low of $177.63 and a one year high of $262.97. The company has a market cap of $9.47 billion, a PE ratio of 32.26, a P/E/G ratio of 1.95 and a beta of 1.13.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, May 2nd. The medical technology company reported $3.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.14. The company had revenue of $737.80 million for the quarter, compared to analyst estimates of $726.85 million. Teleflex had a return on equity of 14.78% and a net margin of 9.82%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company posted $3.09 earnings per share. On average, equities research analysts forecast that Teleflex will post 13.72 EPS for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.68%. The ex-dividend date of this dividend was Thursday, February 29th. Teleflex’s dividend payout ratio (DPR) is currently 21.83%.

Insider Buying and Selling

In other Teleflex news, VP Cameron P. Hicks sold 7,401 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the transaction, the vice president now directly owns 10,050 shares of the company’s stock, valued at approximately $2,261,250. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.43% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Teleflex by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,454,016 shares of the medical technology company’s stock valued at $1,359,904,000 after purchasing an additional 57,132 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Teleflex by 2.1% during the 4th quarter. Wellington Management Group LLP now owns 2,496,566 shares of the medical technology company’s stock valued at $622,494,000 after buying an additional 52,533 shares during the last quarter. Cooke & Bieler LP raised its stake in Teleflex by 5.7% during the fourth quarter. Cooke & Bieler LP now owns 734,965 shares of the medical technology company’s stock worth $183,256,000 after acquiring an additional 39,308 shares during the period. Invesco Ltd. lifted its holdings in Teleflex by 23.3% in the third quarter. Invesco Ltd. now owns 621,445 shares of the medical technology company’s stock worth $122,058,000 after acquiring an additional 117,401 shares during the last quarter. Finally, TD Asset Management Inc boosted its stake in Teleflex by 2.5% in the third quarter. TD Asset Management Inc now owns 481,840 shares of the medical technology company’s stock valued at $94,638,000 after acquiring an additional 11,796 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.